Company / Cost of Revenue
Akebia Therapeutics, Inc. Cost of Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$39.5M
FY2025
5-year range
$39.5M / $145.3M
FY2021-FY2025
Trend
-37.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has declined for 4 consecutive years, from $145M in FY2021 to $39M in FY2025.
Based on SEC 10-K filings.
$39M in FY2025 with a 5-year CAGR of +38.4%.
Improved from $74M to $39M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -22.7%
- 5-Year CAGR
- +38.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Akebia Therapeutics, Inc.'s cost of revenue has declined for 4 consecutive years.
- 5-year CAGR of +38.4%, indicating consistent growth.
- In FY2025, cost of revenue decreased 37.5% year-over-year.
- Peak cost of revenue was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $39.5M | -37.5% |
| FY2024 | $63.2M | -14.8% |
| FY2023 | $74.1M | -13.3% |
| FY2022 | $85.6M | -41.1% |
| FY2021 | $145.3M | +1771.0% |
| FY2020 | $7.8M | +24.3% |
| FY2019 | $6.3M | +0.0% |
| FY2018 | $6.3M | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026